Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524255-32-00

Enrollment

Registered

2026-04-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous squamous cell carcinoma (ccSCC)

Brief summary

Primary translational end points are immunologic, genomic, and pathological correlations of response to cemiplimab in blood and tumor samples.

Detailed description

Flow cytometry assays, Multiplex immunohistochemistry, Single-cell RNA (scRNA) Seq assays, Progression-free survival (PFS), Overall Response Rate (ORR) per RECIST 1.1

Interventions

DRUGLIBTAYO 350 mg concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Primary translational end points are immunologic, genomic, and pathological correlations of response to cemiplimab in blood and tumor samples.	—

Secondary

Measure	Time frame
Flow cytometry assays, Multiplex immunohistochemistry, Single-cell RNA (scRNA) Seq assays, Progression-free survival (PFS), Overall Response Rate (ORR) per RECIST 1.1	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 25, 2026